Published on 21/12/2025
How to Write Clear and Transparent Clinical Trial Results: Step-by-Step Best Practices
Why Writing Style Matters in Trial Result Disclosure
Publishing clinical trial results is not merely about data—it’s about communicating findings in a way that is accurate, transparent, and accessible. Regulatory authorities like the FDA, EMA, and Health Canada have strict formats and timelines, while journals and registries demand clarity, consistency, and transparency. Poorly written results can lead to misinterpretation, rejection by journals, regulatory queries, or worse—public misinformation.
Transparency begins with how trial results are structured and written. A well-documented and clearly communicated result section supports reproducibility, facilitates ethical review, aids patient understanding, and meets global compliance requirements like FDAAA 801 and EU CTR 536/2014.
Core Elements of a Transparent Result Summary
To ensure consistency and clarity, trial results—whether submitted to registries or peer-reviewed journals—should include the following core elements:
- Study Objective & Design: Reiterate the trial’s primary purpose and methodology (e.g., Phase II, randomized, double-blind, placebo-controlled).
- Population Characteristics: Provide demographic and baseline data (e.g., age range: 18–65 years, N=220, 55% female).
- Primary and Secondary Outcomes: Clearly report results for all prespecified outcomes, including numerical data and statistical significance.
- Safety Data: Present adverse events (AEs), serious AEs,
Results should align with the CONSORT (Consolidated Standards of Reporting Trials) guidelines for randomized trials and ICMJE requirements for publications.
Formatting Guidelines for Global Registries
Each clinical trial registry has specific format and field requirements. Let’s consider three key examples:
| Registry | Key Format Requirements | Word/Character Limits |
|---|---|---|
| ClinicalTrials.gov | Structured fields (Participant Flow, Baseline, Outcome Measures, AE Tables) | 4000 characters per field (approx.) |
| EU CTIS | XML upload with PDF lay summary; adverse event categorization; results linked to protocol | Varies by document type |
| ISRCTN | Free-text narrative; CSV results upload; emphasis on lay accessibility | No hard limits, but clarity is critical |
Using templates or automation tools can help sponsors align with structural requirements while maintaining clarity.
Tips for Enhancing Readability and Scientific Integrity
To improve transparency and clarity of trial result writing:
- Use Plain Language: Avoid jargon. Use terms that healthcare professionals and ethics reviewers can easily interpret.
- Write in Active Voice: “The intervention reduced BP by 12 mmHg” is clearer than “BP reduction of 12 mmHg was observed.”
- Maintain Numerical Consistency: Report means, SD, medians, and confidence intervals clearly and consistently.
- Use Visuals Wisely: Include tables and simple graphs where allowed to support comprehension (especially for lay summaries).
- Avoid Redundancy: Don’t restate the same information across multiple result fields or documents.
Example of a clearly written result: “At week 12, the treatment group (N=104) had a mean HbA1c reduction of 1.4% (95% CI: 1.2–1.6), compared to 0.5% (95% CI: 0.3–0.7) in the placebo group (N=106), p<0.001.”
Incorporating Lay Summaries for Public Accessibility
EU CTR now requires a lay summary written in plain language for public accessibility. Best practices include:
- Use Readability Tools: Ensure summaries meet Flesch-Kincaid readability standards (aim for 6th–8th grade level).
- Define Medical Terms: For example, “HbA1c (a measure of long-term blood sugar)” instead of just “HbA1c.”
- Use Short Sentences: Aim for clarity—avoid technical compound sentences.
- Structure Information: Use headings like “What was studied?”, “What were the results?”, and “What do they mean?”
Lay summaries must be included in the EU CTIS within 12 months of trial completion. Canada’s registry also encourages use of patient-centric language in trial disclosures.
Role of Medical Writers and Editorial Review Teams
Transparent and clear result writing is a multidisciplinary task. Medical writers ensure scientific accuracy, while compliance officers verify regulatory adherence. In large sponsors, editorial review teams often include:
- Clinical Data Manager
- Biostatistician
- Medical Writer
- Regulatory Affairs Specialist
- Legal Reviewer (for promotional risk)
Coordinating these stakeholders is key to ensuring final output aligns with both scientific integrity and legal compliance.
Avoiding Pitfalls in Trial Result Writing
Some common mistakes that compromise clarity and transparency:
- Not Reporting All Outcomes: Only listing positive outcomes while omitting negative or neutral results leads to bias.
- Overinterpreting Data: Claiming efficacy when statistical significance isn’t achieved.
- Using Promotional Language: Terms like “game-changer” or “breakthrough” have no place in result reporting.
- Failing to Match Registry Results to Protocol: Discrepancies raise red flags during audits.
Having a checklist and conducting a final review against registry protocol, statistical analysis plan (SAP), and CSR helps ensure consistency and completeness.
Conclusion: Aligning Clarity with Compliance
Writing clinical trial results is a delicate balance between scientific rigor and accessibility. Clarity is not optional—it is a regulatory and ethical mandate. Following structured best practices, using templates, and incorporating feedback from multi-disciplinary teams can ensure that results serve all stakeholders: regulators, researchers, ethics committees, and most importantly, patients.
Transparent and well-written trial results reduce regulatory risk, enhance scientific credibility, and fulfill the moral obligation owed to trial participants. As disclosure regulations tighten worldwide, clear writing is no longer a skill—it’s a strategic necessity.